Systemic lupus erythematosus (SLE) is a major cause of death in young women that goes largely unrecognized due to its exclusion from an annual nationwide ranking, a new U.S. study shows. Based on these findings, researchers believe that public health and research programs dedicated to the disease are warranted, and…
A new mechanism that helps to maintain immune self-tolerance and prevent autoimmune diseases was discovered using human cells and mice, new research shows. The findings identify a novel pathway that regulates tolerance in B-cells, which may provide a new diagnostic marker and therapeutic targets to…
The Lupus Research Alliance and its newly formed affiliate Lupus Therapeutics will collaborate with Bristol-Myers Squibb (BMS) to test a novel investigational candidate BMS-986165 as a potential therapy for lupus. BMS-986165 is the first of its kind to be tested in lupus. The medicine is a potent,…
Teen and young women with systemic lupus erythematosus (SLE) have a higher risk of adverse pregnancy-related outcomes, including hypertensive disorders, maternal death, preterm birth, spontaneous abortion, and induced abortion, according to researchers. Their study, “Adverse pregnancy outcomes in adolescents and young women with systemic lupus erythematosus: a…
Iron deficiency, measured through the size variation of red blood cells, is correlated with increased fatigue in systemic lupus erythematosus (SLE) patients, research shows. The association seems to be independent of age, ethnicity, or geographical location. This is the first time a blood biomarker has been linked to fatigue…
Benlysta (belimumab) reduces disease activity, relapses, and the need for corticosteroids in patients with a high degree of systemic lupus erythematosus (SLE) disease activity, according to a new analysis of a Phase 3 clinical trial. The study, “Efficacy and safety of subcutaneous belimumab in anti‐dsDNA‐positive, hypocomplementemic…
Infection with the Epstein-Barr virus (EBV) that causes mononucleosis can increase a person’s risk of developing any of seven major autoimmune diseases, including systemic lupus erythematosus, new and possibly ground-breaking research indicates. The study, “Transcription factors operate across disease loci, with…
Lupuzor (rigerimod, or IPP-201101) combined with standard therapy did not demonstrate a statistically significant response rate in systemic lupus erythematosus (SLE) patients over standard care alone, failing the primary goal of a Phase 3 clinical trial, according to top-line results. Although not statistically significant, the investigational treatment did, however, show…
The Lupus Research Alliance recently announced the nine winners of its Novel Research Grants, to support innovative research on lupus. The grants support research into the complexity of lupus from different perspectives. Among the nine winners, studies vary from testing new and existing therapies, to exploring paths for…
Treatment with 150 mg atacicept significantly improves outcomes in systemic lupus erythematosus (SLE) patients with high disease activity, data from a Phase 2b clinical trial show. The results of the trial were presented recently at the 2018 SLEuro Annual Meeting in Dusseldorf, Germany in a poster titled “SRI response,…